Flualprazolam is an analytical reference material categorized as a benzodiazepine. This product is intended for research and forensic purposes only. For more information about Flualprazolam or any other reagent, please visit https://rcchemsupply.com/
Flualprazolam is available in 5g ,10g , 50g , 100g , 100g , 250g , 500g , 1000g , 2000g .
- Product Name: FLUALPRAZOLAM
- IUPAC Name: 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
- Cas Number: 28910-91-0
- Molecular Formula: C17H12ClFN4
- Appearance: Powder
- Application: Research purposes
- Availability: In Stock
- Packaging: Aluminum foil bag package done by an expert
- Purity: 99.8%
- Origin: China
- Minimum order: 10 Grams
- Production Capacity: 100KG/WEEK
- Transportation: Delivery done by EMS, DHL, FEDEX, UPS and TNT
Flualprazolam is contraindicated in pregnancy, breastfeeding, agitation, neuroleptic malignant syndrome, seizures, and during any case of alcohol or drug abuse, idiopathic hypersomnia, and dysesthesia. It is also contraindicated in patients with known hypersensitivity to fluoxetine and the other antipsychotics, in patients with a history of extrapyramidal side effects, and in patients with transient bradycardia, hyperthyroidism, anticholinergic effects, or cardiac arrhythmias.
What is flualprazolam used for?
Use in Patients with Dementia or Moderate to Severe Cognitive Impairment. It should be used with caution in patients with dementia or moderate to severe cognitive impairment, with any of the following stipulations: Has a history of agitation or aggression, but has responded well to a higher dose of antipsychotics. Has experienced a rapid onset of akathisia or catatonia. Has any neurological, musculoskeletal, or pulmonary disorders, including cerebellar or pulmonary neuropathies or a history of pneumothorax, angina, hypokalemia, or hypoxia. Has taken anticholinergic medications in the past, or that were administered in combination with a cholinergic agent, such as benzodiazepines, in the dose that is likely to be used for the treatment of akathisia.
Buy flualprazolam usa vendor
Not recommended for use in pregnant or breastfeeding women. Its a hepatotoxic drug and pregnant or breastfeeding women should not take this drug.
Adverse reactions occurring in greater than or equal to 1% of patients treated in clinical trials included akathisia and hallucinatory experiences. Adverse reactions occurring in less than 1% of patients treated in clinical trials included hypotension and anorexia. A full listing of adverse reactions may be found in the complete prescribing information.
Should not be co-administered with selective serotonin reuptake inhibitors (SSRIs). Flualprazolam should be avoided in patients with a known hypersensitivity to the active substance or to any of the excipients. Should not be used in combination with anticholinergic agents. Flualprazolam should not be used in patients with a history of epilepsy or polyneuropathy. Very rarely, coadministration of benzodiazepines or thienodiazepines may increase the risk of akathisia, agitation, and hypoxemia. Avoid coadministration with benzodiazepines or thienodiazepines.
Contraindicated in patients with a history of substance dependence or an alcohol abuse disorder, as Flualprazolam may interfere with the withdrawal of these medications. Adverse Reactions in Older Patients like dizziness, amnesia, drowsiness, sedation, and tremor may be observed in older patients.
Infusion-related Reactions Infusion-related reactions, including pruritus, chills, and myalgia, may occur following intravenous administration of Flualprazolam. Please see the full Prescribing Information and Medication Guide for Flualprazolam at https://www.flualprazolam.com/docs/Prescribing_Information.pdf.
Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases and is working to advance orally-administered complex molecules that it believes can be alternatives to the invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.